Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorEmory University

About this trial

This clinical trial develops and studies how well mobile health (m-Health) patient navigation (PN) strategies work to improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya. Although highly curable, breast cancer kills thousands of women in developing countries yearly. Mammography (MMG) is used for the early detection of breast cancer by creating a picture of the breast using film or a computer. Despite the availability of MMG in all 47 counties in Kenya, screening remains low in eligible women. Early detection of breast cancer may also be improved through access to high quality clinical breast exams (CBE). However, primary care providers in Kenya face barriers to incorporating CBE into practice, including limited patient awareness of breast cancer screening. m-Health uses applications on mobile phones to deliver PN directly to the patients. The PN strategies in this study include digital platforms and tools to help with education, reminders, navigation, and motivation around breast cancer screening. This may improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

AIM 1: All members of BREAKTHROUGH's Stakeholder Advisory Board (SAB) breast cancer working group

AIM 1: Participants (patients and health providers) from primary health care clinics in Nairobi County

AIM 1: Will include women (patients) aged over 35 years and speak either Kiswahili or English

Have never undergone MMG screening

Disqualifiers

AIM 1: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study

AIM 2: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study

AIM 3: Women undergoing breast cancer treatment and women aged 70 years and above will be excluded

AIM 4: Members of SAB breast cancer group, and health facilities leadership who will be unwilling and unable to consent will be excluded

Trial design

Design model

Sequential

Treatments tested in this trial

  • Best Practice

    Other intervention

    Receive EUC

  • Discussion

    Other intervention

    Complete a focus group

  • Interview - Stakeholder

    Other intervention

    Complete stakeholder interview

  • Interview - Key Informant

    Other intervention

    Complete key informant interview

  • Interview - Ancillary studies

    Other intervention

    Ancillary studies

  • Patient Navigation - C Components

    Behavioral

    Receive adapted m-Health PN strategy C components

  • Patient Navigation - B components

    Behavioral

    Receive adapted m-Health PN strategy B components

  • Patient Navigation - A components

    Behavioral

    Receive adapted m-Health PN strategy A components

  • Survey Administration

    Other intervention

    Complete EBI adaptation and implementation surveys

  • Survey Administration - Ancillary studies

    Other intervention

    Ancillary studies

Treatment groups

800 Participants
are divided into 11 treatment groups

11

Treatment groups

See each treatment group below.

Group A: Aim 1 (focus group)Experimental treatment 1 intervention
Group B: Aim 2 group I (stakeholder interview, surveys)Experimental treatment 2 interventions
Group C: Aim 2 group II (key informant interview, surveys)Experimental treatment 2 interventions
Group D: Aim 3 arm 1 (EUC)Active comparator 3 interventions
Group E: Aim 3 arm 2 (EUC, PN strategy C)Experimental treatment 4 interventions
Group F: Aim 3 arm 3 (EUC, PN strategy B)Experimental treatment 4 interventions
Group G: Aim 3 arm 4 (EUC, PN strategy B and C)Experimental treatment 5 interventions
Group H: Aim 3 arm 5 (EUC, PN strategy A)Experimental treatment 4 interventions
Group I: Aim 3 arm 6 (EUC, PN strategy A and C)Experimental treatment 5 interventions
Group J: Aim 3 arm 7 (EUC, PN strategy A and B)Experimental treatment 5 interventions
Group K: Aim 3 arm 8 (EUC, PN strategy A, B, and C)Experimental treatment 6 interventions

Trial outcomes

Primary outcomes

1

Adapted evidence-based intervention (EBI) delivery strategies (Aim 1)

The research team will have two independent members who will translate and code the transcripts of the focus group discussions (FGDs). They will be using the Capability, Opportunity, and Motivation-based Behavior model to categorize and code the barriers and opportunities associated with the implementation of candidate evidence-based intervention. Topic prompts related to factors that facilitate EBI implementation will be thematically coded to inform selection and adaptation of EBI delivery (implementation) strategies.

Time frame
Up to 2 years
2

Health system resources, training, and requirements for EBI implementation (Aim 2)

Will use descriptive statistics to analyze quantitative data from the Service Availability and Readiness Assessment survey, service mapping, Technology Acceptance Model, and Organizational Readiness for Implementing Change. FGDs and key informant interviews will be digitally recorded, transcribed, then translated into English by an experienced study translator. Experienced study team members, supported by trainees, will develop codebooks using an iterative, abductive technique, which allows coders to reference the Consolidated Framework for Implementation Research (CFIR), the process will involve remaining receptive to informative deviations. The coding process will start with reading the transcripts individually to detect initial themes, patterns, and questions that can generate ideas. Then, focused coding will be conducted to identify concepts that cluster together, organize thoughts, identify major themes that emerge, and connect them to relevant CFIR constructs.

Time frame
Up to 4 years
3

Access to screening mammography (MMG) for eligible asymptomatic women (Aim 3)

The primary method of data collection will be through verification of completion of navigation points in the care pathway of each participant. The data will also be verified by a trained research assistant at 3 and 6 months and study completion through review of medical records in the health facilities and phone communication audits with the participants. Will utilize blinded outcome assessors to check for fidelity and other outcomes that require data collection for verification through manual review of facility medical records (paper-based patient registers).

Time frame
Up to 6 months
4

Access to diagnostic MMG or breast ultrasound for women who have a breast abnormality identified on clinical breast examination offered at the clinic (Aim 3)

The primary method of data collection will be through verification of completion of navigation points in the care pathway of each participant. The data will also be verified by a trained research assistant at 3 and 6 months and study completion through review of medical records in the health facilities and phone communication audits with the participants. Will utilize blinded outcome assessors to check for fidelity and other outcomes that require data collection for verification through manual review of facility medical records (paper-based patient registers).

Time frame
Up to 6 months

Secondary outcomes

1

Time to MMG screening (Aim 3)

The primary method of data collection will be through verification of completion of navigation points in the care pathway of each participant. The data will also be verified by a trained research assistant at 3 and 6 months and study completion through review of medical records in the health facilities and phone communication audits with the participants. Will utilize blinded outcome assessors to check for fidelity and other outcomes that require data collection for verification through manual review of facility medical records (paper-based patient registers).

Time frame
Up to 2 years
2

Time to diagnostic MMG (Aim 3)

The primary method of data collection will be through verification of completion of navigation points in the care pathway of each participant. The data will also be verified by a trained research assistant at 3 and 6 months and study completion through review of medical records in the health facilities and phone communication audits with the participants. Will utilize blinded outcome assessors to check for fidelity and other outcomes that require data collection for verification through manual review of facility medical records (paper-based patient registers).

Time frame
Up to 2 years
3

Time to breast ultrasound (Aim 3)

The primary method of data collection will be through verification of completion of navigation points in the care pathway of each participant. The data will also be verified by a trained research assistant at 3 and 6 months and study completion through review of medical records in the health facilities and phone communication audits with the participants. Will utilize blinded outcome assessors to check for fidelity and other outcomes that require data collection for verification through manual review of facility medical records (paper-based patient registers).

Time frame
Up to 2 years
4

Time to breast biopsy (if required) (Aim 3)

The primary method of data collection will be through verification of completion of navigation points in the care pathway of each participant. The data will also be verified by a trained research assistant at 3 and 6 months and study completion through review of medical records in the health facilities and phone communication audits with the participants. Will utilize blinded outcome assessors to check for fidelity and other outcomes that require data collection for verification through manual review of facility medical records (paper-based patient registers).

Time frame
Up to 2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Emory University

Lead sponsor

National Cancer Institute (NCI)

Collaborator